ReviewJournal of thrombosis and thrombolysis2002
Argatroban.
Review in Journal of thrombosis and thrombolysis, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Pooled it
- VLX-1005, but not argatroban, prevents ITAM-mediated platelet activation and heparin-induced thrombocytopenia.Blood vessels, thrombosis & hemostasis · 2026Article
- Enantiocomplementary Bioreduction of Flexible Ring N-(3-Oxobutyl)Heterocycles Providing Enantiopure Chiral Fragments for Drug Discovery.Chembiochem : a European journal of chemical biology · 2025Article
- Successful Nafamostat Mesilate Administration for Andexanet Alfa-Induced Heparin Resistance.Cureus · 2023Article
- Role of direct oral anticoagulants in patients with kidney disease.Kidney international · 2020Review
- Combination of therapeutic hypothermia and other neuroprotective strategies after an ischemic cerebral insult.Current neuropharmacology · 2014Article
- Article
- Argatroban in short-term percutaneous ventricular assist subsequent to heparin-induced thrombocytopenia.The journal of extra-corporeal technology · 2008Article
- Efficacy of anti-coagulant treatment with argatroban on cardioembolic stroke.Journal of neurology · 2007Article
- [Argatroban: pharmacological properties and anaesthesiological aspects].Der Anaesthesist · 2006Review
- Clinician update: direct thrombin inhibitors in acute coronary syndromes.Journal of thrombosis and thrombolysis · 2003Article
- [SBA 2020: Regional anesthesia guideline for using anticoagulants update].Brazilian journal of anesthesiology (Elsevier)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antithrombotic and antiplatelet therapies are the cornerstones of management of cardiovascular disorders today. Due to the safety and efficacy limitations of the classic antithrombotic, unfractionated heparin, considerable effort has been directed at developing novel anticoagulants. Direct thrombin inhibitors as a class of drugs offer inhibition of clot-bound as well as fluid-phase thrombin and a more predictable anticoagulant response. Specifically, argatroban, a synthetic small molecule direct thrombin inhibitor, selectively inhibits the catalytic site of thrombin in a reversible manner. Overall, argatroban's short half-life, ease of monitoring with an activated partial thromboplastin time, and safety in renal failure patients make this drug the preferable mode therapy for prevention of thrombosis in heparin-induced thrombocytopenia. The role of adjunctive argatroban therapy in acute coronary syndromes and during percutaneous coronary intervention is currently being studied.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.